» Articles » PMID: 31663113

Highly Oxidized Low-density Lipoprotein Mediates Activation of Monocytes but Does Not Confer Interleukin-1β Secretion nor Interleukin-15 Transpresentation Function

Overview
Journal Immunology
Date 2019 Oct 31
PMID 31663113
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidized low-density lipoprotein (LDL) contributes to cardiovascular disease in part by mediating activation and maturation of monocytes and macrophages. Furthermore, co-localization studies using histochemical approaches have implicated a potential role for oxidized LDL as a mediator of interleukin-15 (IL-15) expression in myeloid cells of atherosclerotic plaque. The latter activity could be an important pro-inflammatory mechanism that mediates myeloid cell/T-cell crosstalk. Here, we examined the responses of primary human monocytes to highly oxidized LDL molecules. Oxidized LDL readily induced secretion of chemokines MCP-1 (CCL2) and GRO-α (CXCL1) but unlike lipopolysaccharide (LPS), has limited capacity to induce a variety of other cytokines including tumor necrosis factor-α, IL-6, IL-1β and interferon-γ-induced protein-10 and also displayed a poor capacity to induce p-Akt or P-S6 signaling. Failure of oxidized LDL to induce IL-1β secretion was associated with limited induction of caspase-1 activation. Furthermore, despite finding evidence that oxidized LDL could enhance the expression of IL-15 and IL-15 receptor expression in monocytes, we found no evidence that it could confer IL-15 transpresentation capability to these cells. This observation contrasted with induction of IL-15 transpresentation in lipopolysaccharide-stimulated monocytes. Overall, our data suggest that highly oxidized LDL is a selective inducer of monocyte activation. Sterile inflammatory mediators, particularly those implicated in Toll-like receptor 4 signaling, may play a role in vascular pathology but the activities of these agents are not uniform.

Citing Articles

Reactive Oxygen Species, a Potential Therapeutic Target for Vascular Dementia.

White A, Talkington G, Ouvrier B, Ismael S, Solch-Ottaiano R, Bix G Biomolecules. 2025; 15(1).

PMID: 39858401 PMC: 11761268. DOI: 10.3390/biom15010006.


Investigation of the Correlation Between the Polymorphism/Expression Level of RANTES and Its Receptor CCR5 Gene Promoter and Type 2 Diabetes Mellitus.

Chen J, Guo W, Yin H, Ma L, Li S, Li H Diabetes Metab Syndr Obes. 2023; 16:213-223.

PMID: 36760585 PMC: 9884060. DOI: 10.2147/DMSO.S398264.


Survey of In Vitro Model Systems for Investigation of Key Cellular Processes Associated with Atherosclerosis.

Ramji D, Ismail A, Chen J, Alradi F, Al Alawi S Methods Mol Biol. 2022; 2419:39-56.

PMID: 35237957 DOI: 10.1007/978-1-0716-1924-7_3.


Novel Strategies to Combat CMV-Related Cardiovascular Disease.

Vasilieva E, Gianella S, Freeman M Pathog Immun. 2020; 5(1):240-274.

PMID: 33089035 PMC: 7556413. DOI: 10.20411/pai.v5i1.382.

References
1.
Brinkley T, Nicklas B, Kanaya A, Satterfield S, Lakatta E, Simonsick E . Plasma oxidized low-density lipoprotein levels and arterial stiffness in older adults: the health, aging, and body composition study. Hypertension. 2009; 53(5):846-52. PMC: 2692957. DOI: 10.1161/HYPERTENSIONAHA.108.127043. View

2.
Williams J, Huang L, Randolph G . Cytokine Circuits in Cardiovascular Disease. Immunity. 2019; 50(4):941-954. PMC: 6924925. DOI: 10.1016/j.immuni.2019.03.007. View

3.
Rhoads J, Lukens J, Wilhelm A, Moore J, Mendez-Fernandez Y, Kanneganti T . Oxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcγR Cooperation and Is Dependent on CARD9. J Immunol. 2017; 198(5):2105-2114. PMC: 5318843. DOI: 10.4049/jimmunol.1601563. View

4.
Grivel J, Ivanova O, Pinegina N, Blank P, Shpektor A, Margolis L . Activation of T lymphocytes in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2011; 31(12):2929-37. PMC: 3401061. DOI: 10.1161/ATVBAHA.111.237081. View

5.
Coll R, Robertson A, Chae J, Higgins S, Munoz-Planillo R, Inserra M . A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21(3):248-55. PMC: 4392179. DOI: 10.1038/nm.3806. View